The Genetic Landscape of Gastrointestinal Stromal Tumor Lacking KIT and PDGFRA Mutations

Overview

Journal Endocrine

Specialty Endocrinology

Date 2014 Jul 17

PMID 25027296

Citations 15

Authors

Sosipatros A Boikos

Constantine A Stratakis

Affiliations

Soon will be listed here.

Abstract

About 10-15 % of adult gastrointestinal stromal tumors (GISTs) and 85 % of pediatric GISTs do not have mutations in the KIT or PDGFRA genes and are generally classified as KIT/PDGFRA wild type (WT). Recent studies have shown that this group of KIT/PDGFRA WT GISTs is quite heterogeneous in terms of clinical phenotype, genetic etiology, and molecular pathways. Succinate dehydrogenase subunit (SDH)-deficient GISTs, which include tumors that are part of multiple endocrine neoplasia syndromes, are the newest group of KIT/PDGFRA WT GIST to be molecularly elucidated. This review aims to describe the different genetic subgroups of KIT/PDGFRA WT GIST, with a special focus on the SDH-deficient GIST.

Citing Articles

MicroRNA expression signature in gastrointestinal stromal tumour & their molecular & histological features.

Ghani A, Singh H, Kumar H, Vaiphei K Indian J Med Res. 2024; 160(1):118-127.

PMID: 39382501 PMC: 11463855. DOI: 10.25259/ijmr_2567_22.

Molecular Mechanisms of Gastrointestinal Stromal Tumors and Their Impact on Systemic Therapy Decision.

Unk M, Novakovic B, Novakovic S Cancers (Basel). 2023; 15(5).

PMID: 36900287 PMC: 10001062. DOI: 10.3390/cancers15051498.

Gao F, Wang J, Li C, Xie C, Su M, Zou C Int J Gen Med. 2022; 15:3839-3849.

PMID: 35431569 PMC: 9005359. DOI: 10.2147/IJGM.S357224.

A novel fusion between CDC42BPB and ALK in a patient with quadruple wild-type gastrointestinal stromal tumor.

Huang W, Yuan W, Ren L, Xu C, Luo R, Zhou Y Mol Genet Genomic Med. 2022; 10(5):e1881.

PMID: 35319816 PMC: 9034673. DOI: 10.1002/mgg3.1881.

Abnormal MGMT Promoter Methylation in Gastrointestinal Stromal Tumors: Genetic Susceptibility and Association with Clinical Outcome.

Lou L, Zhang W, Li J, Wang Y Cancer Manag Res. 2020; 12:9941-9952.

PMID: 33116851 PMC: 7568426. DOI: 10.2147/CMAR.S269388.

References

Ganjoo K, Villalobos V, Kamaya A, Fisher G, Butrynski J, Morgan J . A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib. Ann Oncol. 2013; 25(1):236-40. PMC: 4271129. DOI: 10.1093/annonc/mdt484. View

Carney J, Stratakis C . Familial paraganglioma and gastric stromal sarcoma: a new syndrome distinct from the Carney triad. Am J Med Genet. 2002; 108(2):132-9. DOI: 10.1002/ajmg.10235. View

Chou A, Chen J, Clarkson A, Samra J, Clifton-Bligh R, Hugh T . Succinate dehydrogenase-deficient GISTs are characterized by IGF1R overexpression. Mod Pathol. 2012; 25(9):1307-13. DOI: 10.1038/modpathol.2012.77. View

Fox E, Widemann B, Chuk M, Marcus L, Aikin A, Whitcomb P . Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma. Clin Cancer Res. 2013; 19(15):4239-48. PMC: 4274128. DOI: 10.1158/1078-0432.CCR-13-0071. View

Heinrich M, Corless C, Duensing A, McGreevey L, Chen C, Joseph N . PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003; 299(5607):708-10. DOI: 10.1126/science.1079666. View

Tahiliani M, Koh K, Shen Y, Pastor W, Bandukwala H, Brudno Y . Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science. 2009; 324(5929):930-5. PMC: 2715015. DOI: 10.1126/science.1170116. View

Heinrich M, Owzar K, Corless C, Hollis D, Borden E, Fletcher C . Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest.... J Clin Oncol. 2008; 26(33):5360-7. PMC: 2651078. DOI: 10.1200/JCO.2008.17.4284. View

Jasperson K, Kohlmann W, Gammon A, Slack H, Buchmann L, Hunt J . Role of rapid sequence whole-body MRI screening in SDH-associated hereditary paraganglioma families. Fam Cancer. 2013; 13(2):257-65. DOI: 10.1007/s10689-013-9639-6. View

Miettinen M, Lasota J . Gastrointestinal stromal tumors. Gastroenterol Clin North Am. 2013; 42(2):399-415. PMC: 3644178. DOI: 10.1016/j.gtc.2013.01.001. View

10.

Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S . Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998; 279(5350):577-80. DOI: 10.1126/science.279.5350.577. View

11.

Oudijk L, Gaal J, Korpershoek E, van Nederveen F, Kelly L, Schiavon G . SDHA mutations in adult and pediatric wild-type gastrointestinal stromal tumors. Mod Pathol. 2012; 26(3):456-63. DOI: 10.1038/modpathol.2012.186. View

12.

Pasini B, Matyakhina L, Bei T, Muchow M, Boikos S, Ferrando B . Multiple gastrointestinal stromal and other tumors caused by platelet-derived growth factor receptor alpha gene mutations: a case associated with a germline V561D defect. J Clin Endocrinol Metab. 2007; 92(9):3728-32. DOI: 10.1210/jc.2007-0894. View

13.

Chompret A, Kannengiesser C, Barrois M, Terrier P, Dahan P, Tursz T . PDGFRA germline mutation in a family with multiple cases of gastrointestinal stromal tumor. Gastroenterology. 2003; 126(1):318-21. DOI: 10.1053/j.gastro.2003.10.079. View

14.

Selak M, Armour S, MacKenzie E, Boulahbel H, Watson D, Mansfield K . Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell. 2005; 7(1):77-85. DOI: 10.1016/j.ccr.2004.11.022. View

15.

Wells Jr S, Gosnell J, Gagel R, Moley J, Pfister D, Sosa J . Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol. 2010; 28(5):767-72. PMC: 2834392. DOI: 10.1200/JCO.2009.23.6604. View

16.

Miettinen M, Wang Z, Sarlomo-Rikala M, Osuch C, Rutkowski P, Lasota J . Succinate dehydrogenase-deficient GISTs: a clinicopathologic, immunohistochemical, and molecular genetic study of 66 gastric GISTs with predilection to young age. Am J Surg Pathol. 2011; 35(11):1712-21. PMC: 3193596. DOI: 10.1097/PAS.0b013e3182260752. View

17.

Yang M, Pollard P . Succinate: a new epigenetic hacker. Cancer Cell. 2013; 23(6):709-11. DOI: 10.1016/j.ccr.2013.05.015. View

18.

Agaram N, Wong G, Guo T, Maki R, Singer S, DeMatteo R . Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer. 2008; 47(10):853-9. PMC: 2902874. DOI: 10.1002/gcc.20589. View

19.

Doyle L, Nelson D, Heinrich M, Corless C, Hornick J . Loss of succinate dehydrogenase subunit B (SDHB) expression is limited to a distinctive subset of gastric wild-type gastrointestinal stromal tumours: a comprehensive genotype-phenotype correlation study. Histopathology. 2012; 61(5):801-9. DOI: 10.1111/j.1365-2559.2012.04300.x. View

20.

Miranda C, Nucifora M, Molinari F, Conca E, Anania M, Bordoni A . KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors. Clin Cancer Res. 2012; 18(6):1769-76. DOI: 10.1158/1078-0432.CCR-11-2230. View